THE 2ND GENERATION CA-125

Optimal management of ovarian cancer patients can only be provided usi ng the CA 125 serum test for treatment monitoring, early prediction of outcome and early detection of recurrence. The newly introduced secon d generation CA 125 assays, the Centocor CA 125 II IRMA, the Boehringe r Mannheim Enzymun CA 125 tl and the BYK Liamat CA 125 II are one-step heterologous double-determinant solid phase assays that utilize the M 11 as capture antibody and the original OC 125 as tracer. The CA 125 I I assays will probably replace the original CA 125 assays within a sho rt period of time. For comparison reasons the Abbott IMx CA 125 assay was also included in this study. Highly similar CA 125 distribution pa tterns were obtained with these new CA 125 II assays. Linear regressio n analysis in ovarian cancer patients showed the following: Centocor C A 125 II=0.98xCA 125 IRMA+10.7 (r=0.8717, P<0.0001), Sy\x=89.9; Enzymu n CA 125 II=1.03xCA 125 IRMA+9.0 (r=0.8988, P<0.0001), Sy\x = 81.8; BY K Liamat CA 125 II=1.17xCA 125 IRMA+0.6 (r=0.8930, P<0.0001), Sy\x=96. 8. Our first technical and clinical evaluation of these three new CA 1 25 II assays shows their superior analytical performance, in addition to a high qualitative and quantitative correlation with the original C A 125 IRMA.